We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-11.74%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$434M
AUM Growth
-$119M
Cap. Flow
-$36.8M
Cap. Flow %
-8.48%
Top 10 Hldgs %
36.01%
Holding
127
New
20
Increased
19
Reduced
51
Closed
12

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$6.21M
2
NVMI
Nova
NVMI
+$5.21M
3
MAZE
Maze Therapeutics
MAZE
+$4.28M
4
IMVT icon
Immunovant
IMVT
+$4.07M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.99M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$18.2M
2
MSFT icon
Microsoft
MSFT
+$7.23M
3
META icon
Meta Platforms (Facebook)
META
+$7.12M
4
WIX icon
WIX.com
WIX
+$6.33M
5
MRVL icon
Marvell Technology
MRVL
+$6.16M

Sector Composition

Rank Sector Weight
1 Healthcare 73.67%
2 Technology 12.64%
3 Consumer Discretionary 2.04%
4 Communication Services 2%
5 Utilities 1.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
26
GSK
GSK
$104B
$5.04M 1.16%
130,000
– –
SEDG icon
27
SolarEdge
SEDG
$2.51B
$5M 1.15%
309,216
-65,784
-18% -$1.02M
ETNB
28
DELISTED
89bio
ETNB
$4.5M 1.04%
618,343
+61,811
+11% +$540K
MRUS
29
DELISTED
Merus
MRUS
$4.48M 1.03%
106,532
-24,000
-18% -$1.05M
IMTX icon
30
Immatics
IMTX
$1.18B
$4.15M 0.96%
921,111
– –
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$3.97M 0.91%
181,346
-24,905
-12% -$688K
MAZE
32
Maze Therapeutics
MAZE
$1.49B
$3.91M 0.9%
+355,554
New +$4.28M
PRAX icon
33
CALL
Praxis Precision Medicines
PRAX
$8.58B
$3.79M 0.87%
100,000
+17,000
+20% +$1.06M
TVTX icon
34
Travere Therapeutics
TVTX
$5.2B
$3.58M 0.83%
200,000
-20,700
-9% -$420K
SVRA icon
35
Savara
SVRA
$1.12B
$3.56M 0.82%
1,284,151
+72,618
+6% +$201K
ARWR icon
36
Arrowhead Research
ARWR
$11.9B
$3.54M 0.81%
277,550
+80,000
+40% +$1.45M
DYN icon
37
Dyne Therapeutics
DYN
$4.7B
$3.44M 0.79%
329,262
+93,000
+39% +$1.33M
ANNX icon
38
Annexon
ANNX
$834M
$3.41M 0.78%
1,764,387
+521,348
+42% +$1.74M
JANX icon
39
Janux Therapeutics
JANX
$925M
$3.4M 0.78%
125,840
+57,507
+84% +$2.17M
HELP
40
Cybin Inc
HELP
$485M
$3.34M 0.77%
527,222
-10,889
-2% -$94.3K
IMVT icon
41
Immunovant
IMVT
$7.93B
$3.33M 0.77%
+194,638
New +$4.07M
NVDA icon
42
NVIDIA
NVDA
$4.86T
$3.21M 0.74%
+29,605
New +$3.75M
RZLT icon
43
Rezolute
RZLT
$454M
$3.14M 0.72%
1,081,447
-84,448
-7% -$368K
RNAM
44
DELISTED
Avidity Biosciences
RNAM
$3.13M 0.72%
+106,000
New +$3.3M
AMGN icon
45
Amgen
AMGN
$208B
$3.12M 0.72%
+10,000
New +$2.95M
BIIB icon
46
Biogen
BIIB
$30B
$3.11M 0.72%
22,738
– –
ACOG
47
Alpha Cognition
ACOG
$180M
$3.02M 0.7%
596,992
-23,008
-4% -$134K
VIGL
48
DELISTED
Vigil Neuroscience
VIGL
$2.86M 0.66%
1,604,429
+102,000
+7% +$229K
NTLA icon
49
Intellia Therapeutics
NTLA
$1.49B
$2.71M 0.62%
381,080
-85,000
-18% -$859K
DAWN
50
DELISTED
Day One Biopharmaceuticals
DAWN
$2.66M 0.61%
334,987
– –
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2025 Portfolio in Review

As of Q1 2025, Sphera Funds Management held 127 positions worth $434M, down 21% from $553M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sphera Funds Management withdrew a net $36.8M in Q1 2025, closing 12 positions and reducing 51 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $5.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 73% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Maze Therapeutics worth $3.91M.

  • Sphera Funds Management's largest Q1 2025 buy was Maze Therapeutics: 355,554 shares worth $3.91M.
  • Sphera Funds Management added most to Sarepta Therapeutics in Q1 2025, an estimated $6.21M increase.
  • Sphera Funds Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $18.2M.
  • Sphera Funds Management fully exited Acadia Pharmaceuticals in Q1 2025, selling an estimated $5.29M.
  • Sphera Funds Management's ten largest holdings make up 36% of its $434M portfolio in Q1 2025.
  • Sphera Funds Management opened 20 new positions and closed 12 in Q1 2025.
  • Sphera Funds Management's portfolio value fell 21% quarter-over-quarter to $434M.

Based on Sphera Funds Management's 13F filing for Q1 2025, filed 15 May 2025.